Literature DB >> 19285621

Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy.

Wouter Jacobs1, Anco Boonstra, J Tim Marcus, Pieter E Postmus, Anton Vonk-Noordegraaf.   

Abstract

BACKGROUND: The aim of our study was to describe the efficacy of addition of intravenous or subscutaneous prostanoids in idiopathic pulmonary arterial hypertension (PAH) patients deteriorating on bosentan or on bosentan-sildenafil.
METHODS: PAH treatment at our hospital is standardized with first-line oral therapy in New York Heart Association class III patients followed by addition of prostanoids on clinical worsening.
RESULTS: Mean improvement in 6-minute walk distance after 4 months of prostanoids was 86 m (p < 0.01) in the bosentan group versus 41 m (p < 0.05) in the bosentan-sildenafil group, and these improvements persisted at long-term follow-up.
CONCLUSIONS: From these results we conclude that addition of subcutaneous or intravenous prostanoids can be efficacious in PAH deteriorating on oral therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19285621     DOI: 10.1016/j.healun.2008.12.003

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  3 in total

1.  Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics.

Authors:  R James White; Yana Levin; Kathleen Wessman; Antonia Heininger; Karen Frutiger
Journal:  Pulm Circ       Date:  2013-11-18       Impact factor: 3.017

2.  Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.

Authors:  Lars Knudsen; Alexander Schurawlew; Nils Nickel; Henning Tiede; Hossein A Ghofrani; Heinrike Wilkens; Ralf Ewert; Michael Halank; Hans Klose; Carlos Bäzner; Jürgen Behr; Marius M Hoeper
Journal:  BMC Pulm Med       Date:  2011-12-01       Impact factor: 3.317

3.  Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension.

Authors:  Howard H Z Thom; Gorana Capkun; Annamaria Cerulli; Richard M Nixon; Luke S Howard
Journal:  BMC Med Res Methodol       Date:  2015-04-12       Impact factor: 4.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.